RFI - Bioequivalence studies for Rifampicinum 150 mg and 300 mg hard capsules
Notice description
Dear,
TZF Polfa is developing a generic product for Rifampicinum 150 mg and 300 mg hard capsules. In connection with the above, we invite you to prepare a proposal for conducting bioequivalence studies in the manner described in the attached RFI Z84_5914_1.
Produkty
1. Conducting bioequivalence studies - 1 szt.
TZF Polfa is developing a generic product for Rifampicinum 150 mg and 300 mg hard capsules. In connection with the above, we invite you to prepare a proposal for conducting bioequivalence studies in the manner described in the attached RFI Z84_5914_1.
Produkty
1. Conducting bioequivalence studies - 1 szt.
Time limit for receipt of tenders
2026-04-30 11:00:00.0
Location
A. Fleminga 2
03-176 Warszawa
03-176 Warszawa
Category assortment
Pharmaceutical products
Buyer details
Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna
A. Fleminga 2
03-176 Warszawa
NIP: 5250000564
A. Fleminga 2
03-176 Warszawa
NIP: 5250000564
